In recent years, China has strived to become a more attractive market for the pharmaceutical industry. Perceived as a market where drugs took longer to get approved and updates to the National Reimbursement Drug List (NRDL) failed to meet industry needs, China is seeking to reinvent itself through streamlined changes to both regulatory and reimbursement processes. One such change is a priority drug review list in which China aims to sharply reduce the time needed for a drug to obtain market authorization in the country.
In this Market Event Summary from the Global Market Access Solutions (GMAS) team, we explore the recent updates to priority review list and what this changing landscape means for the pharmaceutical industry.
Download this Market Event Summary to better understand:
- What is China’s priority review list and how are drugs selected for this program?
- How do timelines for market authorization differ from the traditional market authorization process in China and this program?
- What drugs have been included so far and what were the drivers for some of these selections?
- Which companies and therapeutic areas stand to benefit from changes to one of the world’s largest pharmaceutical markets?